KNG1 Antikörper (AA 2-110) (HRP)

Produktnummer ABIN7346575

Produktdetails anti-KNG1 Antikörper (HRP)

Target: KNG1 (Kininogen 1 (KNG1))

Bindungsspezifität: AA 2-110

Reaktivität: Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser KNG1 Antikörper ist konjugiert mit HRP

Applikation: ELISA

Kreuzreaktivität: Ratte

Aufreinigung: >95%, Protein G purified

Immunogen: Recombinant Rat Kininogen-1 protein (2-110AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu KNG1

Target: KNG1 (Kininogen 1 (KNG1))

Andere Bezeichnung: Kng1 (KNG1 Produkte)

Synonyme: BDK antikoerper, BK antikoerper, KNG antikoerper, Kng antikoerper, KNG2 antikoerper, fb64g01 antikoerper, wu:fb64g01 antikoerper, zgc:103569 antikoerper, kininogen antikoerper, bdk antikoerper, kng antikoerper, KNG1 antikoerper, IHRP antikoerper, KINKG antikoerper, KINKH antikoerper, Kng1 antikoerper, Kngk antikoerper, kininogen 1 antikoerper, kininogen 1 L homeolog antikoerper, inter-alpha-trypsin inhibitor heavy chain family member 4 antikoerper, kininogen 2-like 1 antikoerper, KNG1 antikoerper, Kng1 antikoerper, kng1 antikoerper, kng1.L antikoerper, ITIH4 antikoerper, Kng2l1 antikoerper

Hintergrund:

Background: Kininogens are inhibitors of thiol proteases, (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII, (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes, (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action), (5) LMW-kininogen inhibits the aggregation of thrombocytes, (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.

Aliases: Kng1 antibody, Kng antibody, Kininogen-1 [Cleaved into: Kininogen-1 heavy chain, Bradykinin, Kininogen-1 light chain] antibody

UniProt: P08934

Pathways: ACE Inhibitor Pathway, Glycosaminoglycan Metabolic Process